<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575003</url>
  </required_header>
  <id_info>
    <org_study_id>CYT003-QbG10 08</org_study_id>
    <nct_id>NCT00575003</nct_id>
  </id_info>
  <brief_title>Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis</brief_title>
  <official_title>Double-Blind, Placebo-Controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or
      cat allergy compared to placebo in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conjunctival provocation test with allergen and rhinoconjunctivitis symptoms in daily life</measure>
    <time_frame>on 4 occations over 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the vaccine by collection of adverse events</measure>
    <time_frame>at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Perennial Allergy to House Dust Mite and/or Cat</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT003-QbG10</intervention_name>
    <description>6 subcutaneous injections</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate perennial allergic rhinoconjunctivitis due to hypersensitization
             towards house dust mite and/or cat allergens

        Exclusion Criteria:

          -  Clinical relevant other allergies (perennial or seasonal) that could potentially
             interfere with the patient's study treatment schedule or assessments.

          -  Use of any concomitant medication that could affect the patient's study treatment
             response or assessment results.

          -  Any clinically relevant concomitant disease as judged by the investigator.

          -  Pregnancy or female planning to become pregnant during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra Blaziene</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tartu University Clinic, Out-Patients Department</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Clinic, Lungs Clinic</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The centre of the investigation in treatment of allergic disease</name>
      <address>
        <city>Riga</city>
        <zip>1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNC Uniclinica</name>
      <address>
        <city>Riga</city>
        <zip>1010</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas County Hospital, Department of Pulmonology and Allergology</name>
      <address>
        <city>Kaunas</city>
        <zip>45130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Medical University Hospital, Department of Pulmonology and Immunology</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital, Centre of Pulmonology and Allergology</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <last_update_submitted>April 24, 2009</last_update_submitted>
  <last_update_submitted_qc>April 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Philipp Mueller</name_title>
    <organization>Cytos Biotechnology AG</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

